PRLD Prelude Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRLD

Price (delayed)

$4.31

Market cap

$343.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$331.87M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 39
Highlights
The equity has surged by 122% since the previous quarter and by 76% year-on-year
The quick ratio has soared by 101% from the previous quarter and by 10% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.preludetx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PRLD

PRLD stock price

How has the Prelude Therapeutics stock price performed over time
Intraday
-11.13%
1 week
-3.58%
1 month
-34.99%
1 year
318.45%
YTD
48.62%
QTD
-19.14%

Financial performance

How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$22.42M
Gross profit
$22.42M
Operating income
-$67.4M
Net income
-$60.49M
Gross margin
100%
Net margin
-269.7%
The net margin has soared by 85% YoY and by 42% QoQ
PRLD's operating margin has soared by 84% YoY and by 40% from the previous quarter
Prelude Therapeutics's net income has surged by 51% YoY and by 22% QoQ
PRLD's operating income has surged by 50% year-on-year and by 20% since the previous quarter

Price vs fundamentals

How does PRLD's price correlate with its fundamentals

Growth

What is Prelude Therapeutics's growth rate over time

Valuation

What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
2.57
P/S
18.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.8
The EPS has surged by 55% year-on-year and by 27% since the previous quarter
The equity has surged by 122% since the previous quarter and by 76% year-on-year
The stock's P/B is 81% above its 5-year quarterly average of 1.6 and 7% above its last 4 quarters average of 2.7
The revenue is up by 34% since the previous quarter
The stock's price to sales (P/S) is 23% more than its last 4 quarters average of 17.3

Efficiency

How efficient is Prelude Therapeutics business performance
The return on sales has surged by 85% year-on-year and by 42% since the previous quarter
The ROA has grown by 44% YoY and by 33% from the previous quarter
Prelude Therapeutics's ROIC has increased by 36% from the previous quarter and by 23% YoY
PRLD's return on equity is up by 36% since the previous quarter and by 29% year-on-year

Dividends

What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRLD.

Financial health

How did Prelude Therapeutics financials performed over time
The quick ratio has soared by 101% from the previous quarter and by 10% YoY
The current ratio has soared by 100% since the previous quarter and by 11% year-on-year
The debt is 87% lower than the equity
The equity has surged by 122% since the previous quarter and by 76% year-on-year
PRLD's debt to equity has dropped by 55% since the previous quarter and by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.